Exelixis (EXEL) Valuation Check After ASCO 2026 Data Spotlight And New Merck Trial Collaboration

Simply Wall St.05-28

Exelixis (EXEL) has put fresh attention on its oncology pipeline after announcing extensive CABOMETYX and zanzalintinib data presentations at the 2026 ASCO meeting, along with a new colorectal cancer ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2638654507?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/28338-main-header/1585188087119","is_english":true,"pubTime":"2026-05-28 12:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2638654507","market":"hk","top_or_hot":-1,"title":"Exelixis (EXEL) Valuation Check After ASCO 2026 Data Spotlight And New Merck Trial Collaboration","media":"Simply Wall St.","content":"<div>\n<p>Exelixis (EXEL) has put fresh attention on its oncology pipeline after announcing extensive CABOMETYX and zanzalintinib data presentations at the 2026 ASCO meeting, along with a new colorectal cancer ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exel/exelixis/news/exelixis-exel-valuation-check-after-asco-2026-data-spotlight\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Exelixis (EXEL) Valuation Check After ASCO 2026 Data Spotlight And New Merck Trial Collaboration</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExelixis (EXEL) Valuation Check After ASCO 2026 Data Spotlight And New Merck Trial Collaboration\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-28 12:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exel/exelixis/news/exelixis-exel-valuation-check-after-asco-2026-data-spotlight><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Exelixis (EXEL) has put fresh attention on its oncology pipeline after announcing extensive CABOMETYX and zanzalintinib data presentations at the 2026 ASCO meeting, along with a new colorectal cancer ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exel/exelixis/news/exelixis-exel-valuation-check-after-asco-2026-data-spotlight\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EXEL","symbol_name":"伊克力西斯","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exel/exelixis/news/exelixis-exel-valuation-check-after-asco-2026-data-spotlight","article_id":"2638654507","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/28338-main-header/1585188087119"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exel/exelixis/news/exelixis-exel-valuation-check-after-asco-2026-data-spotlight","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2638654507","pubTimestamp":1779943086,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Exelixis (EXEL) has put fresh attention on its oncology pipeline after announcing extensive CABOMETYX and zanzalintinib data presentations at the 2026 ASCO meeting, along with a new colorectal cancer trial collaboration with Merck.\nSee our latest analysis for Exelixis.\nThe recent ASCO spotlight and Merck collaboration come after a strong run in the stock, with a 30 day share price return of 12.05% and a 3 year total shareholder return of 159.49%. This suggests that momentum has been building...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"EXEL":"伊克力西斯","BK4532":"文艺复兴科技持仓","BK4139":"生物科技"},"translate_title":"ASCO 2026数据聚焦和默克新试验合作后Exelixis(EXEL)估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EXEL":1.98},"content_text":"Exelixis (EXEL) has put fresh attention on its oncology pipeline after announcing extensive CABOMETYX and zanzalintinib data presentations at the 2026 ASCO meeting, along with a new colorectal cancer trial collaboration with Merck. See our latest analysis for Exelixis. The recent ASCO spotlight and Merck collaboration come after a strong run in the stock, with a 30 day share price return of 12.05% and a 3 year total shareholder return of 159.49%. This suggests that momentum has been building around Exelixis' oncology pipeline and perceived risk profile. If Exelixis' cancer focus has your attention, it could be a good time to broaden your watchlist and see what else is emerging in oncology related AI through our 33 healthcare AI stocks With Exelixis stock up 12.05% over 30 days and 159.49% over 3 years, alongside an intrinsic value estimate implying a sizeable discount, you have to ask: is there still upside left, or is the market already pricing in future growth? AdvertisementMost Popular Narrative: 1% Overvalued Exelixis last closed at $50.03, a touch above the most followed fair value estimate of $49.65, which is built on analyst earnings and cash flow assumptions.  The company's substantial free cash flow, strong balance sheet, and disciplined capital allocation (including aggressive share repurchases and prioritization of high-probability, high-value R&D programs) position Exelixis to invest in next-generation discovery and strategic partnerships, which has the potential to improve operating leverage and net margins over time as the product portfolio scales.  Read the complete narrative. Curious what kind of revenue growth, profit margins, and future earnings multiple support that fair value so close to today’s price? The underlying assumptions may surprise you. Result: Fair Value of $49.65 (ABOUT RIGHT) Have a read of the narrative in full and understand what's behind the forecasts. However, that “about right” valuation could shift quickly if CABOMETYX concentration or competitive trial results on colorectal cancer undercut the earnings path analysts are assuming. Find out about the key risks to this Exelixis narrative. Another Take: Earnings Multiple Sends a Different Signal The analyst narrative says Exelixis is about fairly priced around $49.65, yet the current P/E of 15.1x sits well below both peers at 24.5x and a fair ratio of 19.3x. That discount points to either a cushion or a warning sign, depending on how you see future execution risk. To see what the numbers imply if the market moves closer to that fair ratio, take a look at the valuation breakdown in our See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:EXEL P/E Ratio as at May 2026Next Steps With mixed signals on valuation and future execution, it helps to see the full picture for yourself and move quickly to shape your own view using our 4 key rewards and 1 important warning sign. Looking for more investment ideas? If you stop with just one stock, you risk missing other clear opportunities. Use this moment to scan the market and upgrade your watchlist.  Spot potential mispricings quickly by reviewing companies that appear attractively valued on key metrics using the 46 high quality undervalued stocks. Build a steadier income stream by checking out stocks that offer strong yields and resilience through the 9 dividend fortresses. Sleep a little easier at night by focusing on companies that score well on balance sheet strength and fundamentals through the solid balance sheet and fundamentals stocks screener (45 results).   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Exelixis might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2638654507","isCrawlerRequest":true}